Adverse effects of using masks, sanitizer, and gloves among healthcare workers in a tertiary care center during the COVID-19 pandemic: A questionnaire-based study

2021 ◽  
Vol 17 (3) ◽  
pp. 99
Author(s):  
NamrathaK Narayanan ◽  
Anju Anand ◽  
Midhuna Pradeep ◽  
Nandana Shanavas ◽  
Anuvinda Anil ◽  
...  
2021 ◽  
Vol 87 (1) ◽  
Author(s):  
Whitney Lieb ◽  
Yassah Moracious Barclay-Korboi ◽  
Christopher Dike ◽  
Amrin Khander ◽  
Samantha Raymond ◽  
...  

2017 ◽  
Vol 5 (1) ◽  
pp. 1179-1183
Author(s):  
Fares. Almeshal. ◽  
◽  
Feras. Asiri. ◽  
Anas. Alyamani. ◽  
Mohammed. Altuwaijri. ◽  
...  

Author(s):  
Sadia Mansoor ◽  
K. Aparna Sharma ◽  
Piyush Ranjan ◽  
Seema Singhal ◽  
Jyoti Meena ◽  
...  

2013 ◽  
Vol 34 (8) ◽  
pp. 825-831 ◽  
Author(s):  
Nahid Bhadelia ◽  
Rajiv Sonti ◽  
Jennifer Wright McCarthy ◽  
Jaclyn Vorenkamp ◽  
Haomiao Jia ◽  
...  

Background and Objective.Assessing the impact of 2009 influenza A (H1N1) on healthcare workers (HCWs) is important for pandemic planning.Methods.We retrospectively analyzed employee health records of HCWs at a tertiary care center in New York City with influenza-like illnesses (ILI) and confirmed influenza from March 31, 2009, to February 28, 2010. We evaluated HCWs' clinical presentations during the first and second wave of the pandemic, staff absenteeism, exposures among HCWs, and association between high-risk occupational exposures to respiratory secretions and infection.Results.During the pandemic, 40% (141/352) of HCWs with ILI tested positive for influenza, representing a 1% attack rate among our 13,066 employees. HCWs with influenza were more likely to have fever, cough, and tachycardia. When compared with the second wave, cases in the first wave were sicker and at higher risk of exposure to patients' respiratory secretions (P = .049). HCWs with ILI- with and without confirmed influenza-missed on average 4.7 and 2.7 work days, respectively (P = .001). Among HCWs asked about working while ill, 65% (153/235) reported they did so (mean, 2 days).Conclusions.HCWs in the first wave had more severe ILI than those in the second wave and were more likely to be exposed to patients' respiratory secretions. HCWs with ILI often worked while ill. Timely strategies to educate and support HCWs were critical to managing this population during the pandemic.


2021 ◽  
pp. 112067212110593
Author(s):  
Huy V. Nguyen ◽  
Angela S. Li ◽  
Amila R. Silva ◽  
Theodore Leng

Purpose To determine the incidence of ocular adverse effects (AEs) following brolucizumab injection for neovascular age-related macular degeneration at a tertiary academic institution. Design Retrospective, single center cohort study. Participants All patients who received an intravitreal injection of brolucizumab 6 mg for neovascular age-related macular degeneration between October 7, 2019 and July 31, 2020. Methods Medical records of all patients who received brolucizumab 6 mg during the aforementioned time period were carefully reviewed and all ocular adverse effects after injection were charted. Main Outcome Measures Incidence of post-injection ocular AEs, including intraocular inflammation (IOI), and time to development of AEs after injection. Results A total of 77 patients received brolucizumab 6 mg for a total of 115 administrations during the study period. There were 4 AEs (3.5%), including three cases of IOI (2.6%), one central retinal artery occlusion, and one retinal detachment. Two men and two women were affected. Conclusion Ocular AEs, including those leading to severe vision loss, may develop after intravitreal brolucizumab 6 mg. A careful discussion of benefits and risks to brolucizumab should be conducted with all patients. Precis In this first case series of ocular adverse effects after brolucizumab 6 mg injection at a single tertiary care center, the incidence of ocular adverse effects was 3.5%, including a 2.6% incidence of intraocular inflammation.


Sign in / Sign up

Export Citation Format

Share Document